MGMT and malignant glioma: A strategy that involved the pretreatment with the MGMT pseudo-substrate O6-benzylguanine (O6-BG) even if it proved effective in overcoming TMZ resistance, in a subsequent phase II trial showed a positive response in only one out of thirty-four patients with recurrent TMZ-resistant malignant glioma [46,47].